The Cigna Group
CI
$281.45
-0.83%
The Cigna Group is a healthcare company that provides pharmacy benefit management (PBM) and health insurance services, primarily in the United States. It is a market leader in the PBM space, significantly expanded by its 2018 merger with Express Scripts, and serves employers through self-funding arrangements. The current investor narrative centers on Cigna's strategic pivot, including its exit from individual exchange markets and a strategic review of its eviCore unit, as it raises its financial outlook and focuses on core PBM and employer health plan operations.…
CI
The Cigna Group
$281.45
Related headlines
CI 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on The Cigna Group's 12-month outlook, with a consensus price target around $340.92 and implied upside of +21.1% versus the current price.
Average Target
$340.92
0 analysts
Implied Upside
+21.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$290 - $400
Analyst target range
Cigna is covered by 24 analysts, with a consensus recommendation of 'Buy' (mean recommendation 1.54 on a 1-5 scale, where 1 is Strong Buy). The average target price is $340.92, implying approximately +21% upside from the current price of $281.45. The distribution leans bullish, with recent ratings from Bernstein (Outperform), Mizuho (Outperform), UBS (Buy), and Morgan Stanley (Overweight), though Barclays downgraded to Equal Weight and Deutsche Bank moved to Hold, indicating some caution.
The target price range spans from a low of $290.00 to a high of $400.00. The high target of $400 assumes significant multiple expansion and successful execution of the strategic pivot, potentially driven by PBM contract wins and margin improvement. The low target of $290 suggests limited upside and prices in risks such as regulatory changes, competitive pressure, or margin compression. The wide spread ($110) indicates high uncertainty among analysts, but the consensus remains bullish. Recent upgrades from Bernstein and Mizuho, coupled with the raised outlook, support positive sentiment, though the downgrades from Barclays and Deutsche Bank highlight ongoing debate about the company's strategic direction.
Drowning in data?
Find the real signal!
Bulls vs Bears: CI Investment Factors
Cigna presents a compelling value proposition with a forward P/E of 8.41x, a 10.5% free cash flow yield, and consensus analyst upside of 21%. However, persistent relative underperformance, regulatory risks in the PBM segment, and low gross margins temper the bullish case. The strongest evidence supports the bull case: the stock is cheap on earnings and cash flow, and profitability is improving. The single most important tension is whether Cigna can execute its strategic pivot and demonstrate sustainable margin expansion, which would validate the current valuation discount. If margins improve and regulatory risks recede, the stock could re-rate significantly; if not, the discount may persist or widen.
Bullish
- Strong Free Cash Flow Yield: Cigna generates $7.66 billion in trailing free cash flow, yielding approximately 10.5% against its $73.2 billion market cap. This robust cash generation supports shareholder returns and provides a margin of safety.
- Attractive Forward Valuation: The forward P/E of 8.41x is a 32% discount to the trailing P/E of 12.34x, implying expected earnings growth. The PEG ratio of 0.15x further suggests the stock is undervalued relative to its growth rate.
- Consensus Analyst Buy Rating: With a mean recommendation of 1.54 (Strong Buy to Buy) and an average target price of $340.92, analysts see approximately 21% upside from the current price of $281.45. Recent upgrades from Bernstein and Mizuho reinforce positive sentiment.
- Improving Profitability Trends: Net income grew 25% year-over-year to $1.65 billion in Q1 2026, with operating margin expanding from 2.96% in Q4 2025 to 3.44% in Q1 2026. This margin improvement signals operational efficiency gains.
Bearish
- Persistent Relative Underperformance: Cigna's 1-year price change of -5.64% significantly lags the S&P 500's +18.35% gain. The 1-year relative strength of -23.99% indicates sustained selling pressure and investor skepticism.
- Regulatory Overhang on PBM Business: The Evernorth PBM segment accounts for 85% of revenue, exposing Cigna to potential regulatory changes targeting pharmacy benefit managers. Any adverse legislation could compress margins and reduce profitability.
- Low Gross Margins Reflect PBM Mix: Gross margin of 9.45% is well below the industry average of ~15%, driven by the high-revenue, low-margin PBM business. This structural disadvantage limits earnings power compared to pure-play health insurers.
- Strategic Pivot Introduces Execution Risk: Cigna's exit from individual exchange markets and strategic review of eviCore create near-term uncertainty. These divestitures may distract management and could signal a lack of growth avenues in core segments.
CI Technical Analysis
Cigna's stock is in a range-bound consolidation pattern, with a 1-year price change of -5.64%, underperforming the S&P 500's +18.35% gain. The current price of $281.45 sits at 54% of its 52-week range ($239.51–$315.47), indicating it is closer to the low end, which could suggest a value opportunity but also reflects persistent selling pressure. The stock's beta of 0.303 implies it is significantly less volatile than the market, meaning it may offer downside protection but also limited upside participation in rallies.
Short-term momentum is mixed: the 1-month change is -1.28% while the 3-month change is +1.01%, suggesting a slight deceleration from a modest recovery. This divergence from the negative 1-year trend could signal a potential bottoming process, but the relative strength versus the S&P 500 is negative across all periods (1-month relative strength -1.59%, 1-year -23.99%), confirming persistent underperformance. The stock's recent price action shows a pullback from a July high of $304.50 to $281.45, indicating short-term weakness.
Key support is at the 52-week low of $239.51, while resistance is at the 52-week high of $315.47. A breakout above $315.47 would signal a reversal of the downtrend and potential upside to new highs, while a breakdown below $239.51 could accelerate selling. With a beta of 0.303, Cigna is about 70% less volatile than the S&P 500, making it a lower-risk holding in a portfolio context, but its low volatility also means it may lag during market rallies.
Beta
0.30
0.30x market volatility
Max Drawdown
-26.9%
Largest decline past year
52-Week Range
$240-$315
Price range past year
Annual Return
-5.6%
Cumulative gain past year
| Period | CI Return | S&P 500 |
|---|---|---|
| 1m | -1.3% | -0.5% |
| 3m | +1.0% | +4.9% |
| 6m | +3.4% | +9.7% |
| 1y | -5.6% | +18.4% |
| ytd | +0.8% | +9.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CI Fundamental Analysis
Cigna's revenue trajectory is growing steadily, with Q1 2026 revenue of $68.49 billion, up 4.57% year-over-year from $65.50 billion in Q1 2025. The multi-quarter trend shows consistent sequential growth, with Q4 2025 revenue at $72.47 billion and Q3 2025 at $69.75 billion. The Evernorth segment (PBM) generated $58.44 billion in Q1 2026, accounting for 85% of total revenue, while Cigna Healthcare contributed $11.48 billion, highlighting the PBM as the primary growth driver. This growth trajectory supports the investment case, though the reliance on PBM margins introduces regulatory risk.
The company is profitable, with Q1 2026 net income of $1.65 billion and a gross margin of 9.45%, which is typical for the managed care industry. Gross margins have fluctuated, from 11.73% in Q2 2025 to 7.66% in Q4 2025, but improved to 9.45% in Q1 2026, indicating stabilization. Operating margin was 3.44% in Q1 2026, up from 2.96% in Q4 2025, suggesting modest margin expansion. Net income has grown from $1.32 billion in Q1 2025 to $1.65 billion in Q1 2026, a 25% increase, reflecting improving profitability.
Cigna maintains a solid balance sheet with a debt-to-equity ratio of 0.75 and a current ratio of 0.85, indicating manageable leverage and adequate liquidity. Free cash flow (TTM) is $7.66 billion, providing ample capacity for internal growth and shareholder returns. ROE stands at 14.28%, reflecting efficient capital use. The company generated $1.13 billion in operating cash flow in Q1 2026, and with capital expenditures of $267 million, free cash flow was $864 million. The FCF yield (based on market cap of $73.2 billion) is approximately 10.5%, suggesting strong cash generation relative to valuation.
Quarterly Revenue
$68.5B
2026-03
Revenue YoY Growth
+4.6%
YoY Comparison
Gross Margin
9.4%
Latest Quarter
Free Cash Flow
$7.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CI Overvalued?
Since net income is positive, the primary valuation metric is the P/E ratio. The trailing P/E is 12.34x, while the forward P/E is 8.41x, indicating the market expects earnings growth. The gap between trailing and forward P/E implies a 32% expected earnings increase, which aligns with the company's raised outlook. The PEG ratio of 0.15x suggests the stock is undervalued relative to its growth rate, though this low PEG may reflect near-term earnings volatility.
Compared to the industry average (Medical - Healthcare Plans), Cigna's trailing P/E of 12.34x is at a discount to the sector average of approximately 18x (based on typical managed care multiples), representing a 31% discount. This discount is likely justified by Cigna's lower gross margins (9.45% vs. industry average of ~15%) due to its heavy PBM mix, but its strong free cash flow yield and growth trajectory may warrant a narrower discount. The EV/EBITDA of 8.36x is also below the sector average of ~10x, reinforcing a value-oriented valuation.
Historically, Cigna's trailing P/E has ranged from about 7.6x to 32.7x over the past four years. The current 12.34x is near the lower end of that range, suggesting the stock is trading at a discount to its own historical average (which is around 15x). This low valuation implies the market is pricing in pessimistic expectations, potentially due to regulatory overhangs or margin compression, but could also represent a value opportunity if fundamentals improve.
PE
12.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 10x~17x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
8.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Cigna's debt-to-equity ratio of 0.75 is manageable, but the current ratio of 0.85 indicates that current liabilities exceed current assets, posing a liquidity risk in a stress scenario. The company's heavy reliance on the PBM segment (85% of revenue) creates concentration risk; any disruption in that business would materially impact earnings. While free cash flow is strong at $7.66 billion, the low gross margin of 9.45% leaves little room for error if costs rise or pricing power erodes. Earnings volatility is evident from the trailing P/E range of 7.6x to 32.7x over four years, suggesting that net income can fluctuate significantly.
Market & Competitive Risks: Cigna's stock trades at a discount to the industry average P/E of ~18x, but this discount may persist if the market remains skeptical of its growth trajectory. The beta of 0.303 implies low correlation with the market, which can be a double-edged sword: it provides downside protection but also means the stock may lag during rallies, as evidenced by its 1-year relative strength of -23.99%. Regulatory headwinds targeting PBM practices (e.g., transparency requirements, rebate reforms) could compress margins further. Competitive pressure from larger insurers like UnitedHealth and CVS Health's Caremark also threatens market share.
Worst-Case Scenario: A perfect storm of adverse PBM regulation, margin compression, and a broader market selloff could drive Cigna's stock to its 52-week low of $239.51, representing a 15% decline from the current price of $281.45. In a severe scenario, if the company's earnings disappoint and the P/E multiple contracts to 7.6x (the historical low), the stock could fall to approximately $210, a 25% loss. The realistic downside from the current price is about -15% to the 52-week low, but a deeper drawdown of -25% is possible if fundamentals deteriorate.
